ArticleOrphanet journal of rare diseases2025
Assessing the economic burden and health-related quality of life in chinese patients with fibrodysplasia ossificans progressiva: a questionnaire survey analysis.
Article in Orphanet journal of rare diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Assessment of health-related quality of life of patients with gout and hyperuricemia in the Tianjin area according to the SF-6Dv2 scale.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFibrodysplasia ossificans progressiva (FOP) is an ultra-rare, disabling genetic disorder condition that lacks real-world evidence on disease burden. This study aims to investigate the basic characteristics, diagnostic status, prognosis, economic burden and quality of life of FOP patients in China through self-reported data .
methodsAn online survey was conducted through the "China Cloud Platform for Rare Diseases" among patients recruited from the FOP patient organization in March 2023. Patient demographic characteristics, diagnosis, prognosis, healthcare resource usage and costs, and health-related quality of life (HRQoL) data were collected. Health-related quality of life was assessed using EQ-5D-Y for children aged 4-15 and EQ-5D-5L for patients aged ≥ 16. Age subgroup analyses for those aged < 8, 8-15, and ≥ 16 were conducted.
resultsA total of 67 patients (mean age 16.6 ± 10.2 years, 43.3% female) were included. The average delay of confirmed diagnosis was 3.1 ± 4.3 years. 98.5% of patients were disabled due to FOP. Only 38.8% of the patients had outpatient or inpatient visits in the past year. The annual cost per patient was USD 10,820 ± 10,894, with 75.2% being indirect costs. Health utility values were lowest for patients aged ≥ 16 (0.221 ± 0.336), compared to those aged < 8 (0.700 ± 0.163) and those aged 8-15 (0.618 ± 0.202).
conclusionFOP patients suffer long delay diagnosis duration, high disability rates in China. A significant disease burden was driven by high indirect costs and poor quality of life. Patients aged ≥ 16 have the worst health-related quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.